Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced that it has entered into a definitive agreement to be acquired by an affiliate of ArchiMed (“ArchiMed”), an investment firm focused exclusively on the healthcare industry for approximately $1.2 billion.